Theriva biologics announces presentation of data from cohort 1 of the phase 1b/2a clinical trial of syn-004 (ribaxamase) in allogeneic hematopoietic cell transplant recipients

- interim blinded safety and pharmacokinetic data to be presented at the 33rd european congress of clinical microbiology & infectious diseases (eccmid) - - interim blinded safety and pharmacokinetic data to be presented at the 33rd european congress of clinical microbiology & infectious diseases (eccmid) -
TOVX Ratings Summary
TOVX Quant Ranking